PepLabo Download

Rybelsus® and vomiting

Vomiting is less common than nausea on Rybelsus®, but it raises two questions that nausea does not: what happens to a tablet that may not have stayed down, and how quickly fluid loss becomes a problem. This page covers the product-information figures from the US, Europe and Canada, what adverse-event reports add, why the tablet can trigger vomiting, other causes, home measures from MedlinePlus and the signs that need help.

Published · Updated · Rybelsus®: side effects by symptom · Written by the PepLabo editorial team

Vomiting by strength and by country

The US and Canadian tables come from the same two placebo-controlled trials, which the US label numbers Trial 1 and Trial 6 and Canada calls PIONEER 1 and PIONEER 8 [1][3]. Europe pools ten phase 3a trials with 5,707 people on oral semaglutide and gives a frequency class plus an overall percentage [2].

Vomiting with Rybelsus® in official product information, checked 20 October 2026
SourcePlacebo7 mg (4 mg round tablet)14 mg (9 mg round tablet)
US PI, Table 2 [1]3%6%8%
Canadian PM, Table 3 [3]3.0%6.2%8.4%
EU SmPC 4.8, all phase 3a strengths [2]—“Common”: 7% overall—
EU only: PIONEER PLUS [2]—25 mg: 17%50 mg: 18%

Where vomiting sits among the stomach effects

Vomiting trails nausea in every column, but it follows the same climb with tablet strength [1]. It belongs to a wider group: 41% of people on 14 mg, 32% on 7 mg and 21% on placebo had at least one digestive reaction, and 2.0%, 0.6% and 0.3% had one judged severe [1]. Stopping treatment because of digestive reactions happened in 8% on 14 mg, 4% on 7 mg and 1% on placebo in the US count; Canada reports 7.9%, 4.5% and 0.6% [1][3].

Europe adds that most digestive events were mild to moderate and short, and that they led 4% of people to stop [2]. Its patient leaflet notes that vomiting usually passes with time and may be more frequent when the dose is raised to 25 mg or 50 mg [2].

Reports from everyday use

A 2024 study of the US FDA adverse-event database looked at 2,398 reports for semaglutide tablets between mid-2019 and mid-2023; digestive disorders were the most frequent organ group, with 1,735 events [4]. A second analysis compared 2,496 oral records with 16,346 injection records and found the tablet linked more often to digestive events, with a shorter median time to onset: 15 days for the oral form against 22 days for injections [5].

Neither study can say how often vomiting happens. Reports are voluntary, many cases are never sent, and a report does not show that the medicine caused the problem [4][5].

Why the tablet can make you vomit

  • Supported by the labels: semaglutide slows the early emptying of the stomach [1]. The starting schedule exists to reduce digestive reactions, and most vomiting, nausea and diarrhoea reports came while the dose was rising [1].
  • Linked to how much medicine reaches the blood: Canada reports more digestive events in women and people with a lower body mass index, groups with higher exposure [3]. Canada also notes that overdose, studied up to 40 mg in trials, may bring digestive effects such as nausea [3].
  • Unclear: the labels give no figures for people who come from the Ozempic® 0.5 mg injection straight onto 7 mg or 14 mg without the 3 mg month, a route the US label allows a week after the last injection [1].

When a tablet may not have stayed down

All three documents set the same limits: one tablet a day, swallowed whole on an empty stomach with a small amount of water, and a missed dose is skipped so that the next tablet is taken the following day [1][2][3]. None of them covers vomiting shortly after the tablet. They do not say to take another one. Ask your pharmacist or prescriber how to handle it, and note how long after the tablet you were sick.

Taking two tablets the same day counts as too much. The Medication Guide asks you to call your provider or Poison Help (1-800-222-1222 in the US), or to go to an emergency room [1], and Canada says extra side effects such as nausea may follow [3].

Fluids, dehydration and the kidneys

The US label asks prescribers to check kidney function when digestive reactions could drain fluid, especially at the start and after each dose increase, and asks patients to take precautions against fluid loss [1]. Canada says to monitor kidney function particularly in severe nausea, vomiting or diarrhoea [3]. Europe describes kidney function getting worse as a rare outcome of dehydration [2].

MedlinePlus lists thirst, a dry or sticky mouth, passing little urine, dark yellow urine, headache and cramps as early signs of dehydration, and notes that people with diabetes are at higher risk [7]. For treatment it suggests sipping water or sucking ice chips, or drinking water or an electrolyte sports drink, and warns against salt tablets [7].

Causes that have nothing to do with the tablet

Stomach bugs, food poisoning, migraine, pregnancy, motion sickness and slow stomach emptying are all common reasons to vomit, according to MedlinePlus, and appendicitis, ulcers and bowel blockage can start the same way [6]. Two label warnings also include vomiting among possible signs: pancreatitis and gallbladder disease [1][3]. Canada’s leaflet describes intestinal blockage, a reaction of unknown frequency, as severe constipation with pain, bloating and vomiting [3].

Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help

SignWho to contactHow fastSource
Vomit containing blood or dark material that looks like coffee groundsEmergency services (911)EmergencyMedlinePlus [6]
Confusion, fainting or any loss of consciousness during a bout of vomitingEmergency services (911)EmergencyMedlinePlus [7]
Severe stomach pain that does not ease, with or without vomitingStop Rybelsus® and call your provider right awayEmergencyRybelsus® Medication Guide [1]
Vomiting for more than 24 hours, 3 or more times in a day, no fluids kept down for 12 hours or no urine for 8 hoursYour provider right awayTodayMedlinePlus [6]
Pain in the upper stomach with fever, yellow skin or eyes, or clay-coloured stoolsYour provider right awayTodayRybelsus® Medication Guide [1]
Two tablets taken on the same dayYour provider, Poison Help or an emergency roomTodayRybelsus® Medication Guide [1]
Vomiting that keeps returning over days or weeksYour prescriberAt your next appointmentRybelsus® Medication Guide [1]

Questions

Should I take another Rybelsus® tablet if I vomit soon after it?

No label covers this. They allow one tablet a day and say a missed dose is skipped [1][2][3]. Ask your pharmacist or prescriber what to do.

Is vomiting more likely on 14 mg?

Slightly: 8% on 14 mg against 6% on 7 mg and 3% on placebo in the US table [1].

Can vomiting on Rybelsus® affect my kidneys?

It can if it leads to dehydration. The label reports kidney injury after approval, mostly in dehydrated people, and asks you to report vomiting that does not stop [1].

What happens if I take two tablets by mistake?

Call your provider or Poison Help, or go to an emergency room [1]. Canada notes that extra side effects such as nausea may occur [3].

If I switch from Ozempic® injections, do I skip the 3 mg month?

The US label allows people on 0.5 mg injections to start 7 mg or 14 mg tablets one week after the last injection [1]. It gives no separate vomiting figures for that route.

Are sports drinks a good idea after vomiting?

MedlinePlus lists water and electrolyte sports drinks for dehydration and warns against salt tablets [7]. Your provider can advise on food [7].

Sources

Sources checked on

  1. RYBELSUS® and OZEMPIC® tablets Prescribing Information and Medication Guide, Novo Nordisk Revised 1/2026. Sections 2.1, 2.2, 2.4, 5.2, 5.5, 5.6, 5.8, 6.1 (Table 2), 10 and 17; Medication Guide.
  2. Rybelsus: EPAR product information (summary of product characteristics and package leaflet), European Medicines Agency Sections 4.2, 4.4 and 4.8 (Table 1, gastrointestinal adverse reactions); package leaflet sections 3 and 4.
  3. RYBELSUS® (semaglutide tablets) Product Monograph, Novo Nordisk Canada Date of authorization 2026-07-13. Sections 4.2, 4.5, 5, 8.2 (Table 3) and Patient Medication Information.
  4. Xiong S, et al. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023. Diabetes Ther. 2024;15(8):1717–1733 Pharmacovigilance study; full text (PMC). Reports cannot show frequency or cause.
  5. Niu K, et al. Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol. 2024;15:1414268 Pharmacovigilance study comparing oral and injected semaglutide; full text (PMC).
  6. Nausea and vomiting – adults, MedlinePlus Medical Encyclopedia
  7. Dehydration, MedlinePlus Medical Encyclopedia

Set up your lab tonight.

It takes a few minutes. Pep will be waiting.